Qualigen Therapeutics Stock (NASDAQ:QLGN)


OwnershipFinancialsChart

Previous Close

$3.96

52W Range

$3.34 - $30.50

50D Avg

$5.30

200D Avg

$10.97

Market Cap

$2.87M

Avg Vol (3M)

$91.89K

Beta

0.14

Div Yield

-

QLGN Company Profile


Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

4

IPO Date

Jun 23, 2015

Website

QLGN Performance


QLGN Financial Summary


Dec 23Dec 22Dec 21
Revenue-$4.98M$5.65M
Operating Income$-11.30M$-17.94M$-22.66M
Net Income$-12.81M$-21.03M$-17.90M
EBITDA$-11.30M$-14.23M$-27.05M
Basic EPS$-2.53$-5.48$-6.10
Diluted EPS$-2.53$-5.48$-6.10

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q1 21Aug 18, 20 | 5:00 PM

Peer Comparison


TickerCompany
ZVSAZyVersa Therapeutics, Inc.
KPRXKiora Pharmaceuticals, Inc.
PHIOPhio Pharmaceuticals Corp.
REVBRevelation Biosciences, Inc.
NTRBNutriband Inc.
VRAXVirax Biolabs Group Limited
ASMBAssembly Biosciences, Inc.
IMMXImmix Biopharma, Inc.
INDPIndaptus Therapeutics, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
ENTXEntera Bio Ltd.
SLRXSalarius Pharmaceuticals, Inc.
ALRNAileron Therapeutics, Inc.
ATNF180 Life Sciences Corp.